Losartan Potassium Tablet, Film Coated
Product Images NDC 51655-918

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 51655-918). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 918 52 Master Bottle Label Approval Rev A 03 22)

Label for Losartan Potassium Tablets USP 25 mg, film-coated oral tablets supplied in a quantity of 30. The label includes storage instructions, manufacturer details (Northwind Pharmaceuticals), and the product NDC 51655-918-52. It is marked as Rx only and includes standard warnings about storage and child safety.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with the primary endpoint over a 66-month study period for Atenolol (dotted line) and Losartan Potassium (solid line). The chart indicates an adjusted risk reduction of 13% with a p-value of 0.021 for Losartan Potassium relative to Atenolol.*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months for Atenolol and Losartan Potassium. The graph shows a lower percentage for Losartan Potassium, with an adjusted risk reduction of 25% and a p-value of 0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

A figure showing primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol. The left graph displays primary composite event rates and hazard ratios with 95% confidence intervals for age, gender, race, ISH, diabetes, and history of CVD subgroups. The right graph presents stroke (fatal/non-fatal) event rates and hazard ratios for the same subgroups. The hazard ratio scale ranges from 0.3 to 3, indicating relative event risk favoring either Losartan Potassium or Atenolol.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph comparing the percentage of patients with an event over 48 months for Losartan Potassium versus placebo. The solid line represents Losartan Potassium and the dashed line represents placebo. The graph notes a risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of Losartan Potassium, depicted as a molecular diagram showing key atoms and bonds including nitrogen, chlorine, and a potassium ion associated with the molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.